Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Nurix Therapeutics, Inc. (NRIX)  
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30


Download
   
Exchange: N/A
Security Type: Common
Shares Out: 88,818,000
Market Cap: N/A
Last Volume: 0 Avg Vol: 0
52 Week Range: $0 - $0
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

                 
 
Company Profile   Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies designed to modulate cellular protein levels as a treatment approach for cancer and other diseases. Co.'s Bruton's tyrosine kinase (BTK) degrader drug candidates, NX-2127 and NX-5948, are orally available chimeric targeting molecules for the treatment of relapsed or refractory B-cell malignancies and autoimmune indications. Co.'s drug candidate from its E3 ligase inhibitor portfolio, NX-1607, is an orally bioavailable Casitas B-lineage lymphoma proto-oncogene B inhibitor for immuno-oncology indications.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 54,745 72,600 114,573 275,891
Total Sell Value $859,613 $1,068,783 $1,743,809 $4,968,216
Total People Sold 3 3 3 3
Total Sell Transactions 5 9 19 52
End Date 2025-09-04 2025-06-03 2024-12-03 2023-12-04

   
Records found: 251
  Page 1 of 11  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Ring Christine Chief Legal Officer   •       –      –    2025-11-24 4 AS $17.07 $641,697 D/D (37,600) 50,897     -
   Ring Christine Chief Legal Officer   •       –      –    2025-11-24 4 OE $1.86 $69,936 D/D 37,600 88,497     -
   Van Houte Hans Chief Financial Officer   •       –      –    2025-11-03 4 AS $12.56 $78,931 D/D (6,284) 37,592     -
   Ring Christine Chief Legal Officer   •       –      –    2025-10-30 4 S $12.80 $46,631 D/D (3,644) 50,897     -
   Ring Christine Chief Legal Officer   •       –      –    2025-10-30 4 OE $0.00 $0 D/D 10,532 54,541     -
   Van Houte Hans Chief Financial Officer   •       –      –    2025-10-30 4 S $12.80 $40,054 D/D (3,130) 43,876     -
   Van Houte Hans Chief Financial Officer   •       –      –    2025-10-30 4 OE $0.00 $0 D/D 11,494 47,006     -
   Hansen Gwenn Chief Scientific Officer   •       –      –    2025-10-30 4 S $12.80 $52,300 D/D (4,087) 76,751     -
   Hansen Gwenn Chief Scientific Officer   •       –      –    2025-10-30 4 OE $0.00 $0 D/D 11,815 80,838     -
   Gregory Julia P Director   –       •      –    2025-09-17 4 OE $1.86 $19,995 D/D 10,750 10,750     -
   Van Houte Hans Chief Financial Officer   •       –      –    2025-08-01 4 AS $11.03 $59,598 D/D (5,402) 35,512     -
   Van Houte Hans Chief Financial Officer   •       –      –    2025-07-30 4 S $12.01 $51,695 D/D (4,304) 40,914     -
   Van Houte Hans Chief Financial Officer   •       –      –    2025-07-30 4 OE $0.00 $0 D/D 11,494 45,218     -
   Ring Christine Chief Legal Officer   •       –      –    2025-07-30 4 S $12.01 $46,134 D/D (3,841) 44,009     -
   Ring Christine Chief Legal Officer   •       –      –    2025-07-30 4 OE $0.00 $0 D/D 10,532 47,850     -
   Hansen Gwenn Chief Scientific Officer   •       –      –    2025-07-30 4 S $12.01 $51,743 D/D (4,308) 69,023     -
   Hansen Gwenn Chief Scientific Officer   •       –      –    2025-07-30 4 OE $0.00 $0 D/D 11,815 73,331     -
   Van Houte Hans Chief Financial Officer   •       –      –    2025-05-02 4 AS $11.33 $70,243 D/D (6,198) 33,724     -
   Hansen Gwenn Chief Scientific Officer   •       –      –    2025-04-30 4 S $11.50 $38,841 D/D (3,377) 61,516     -
   Hansen Gwenn Chief Scientific Officer   •       –      –    2025-04-30 4 OE $0.00 $0 D/D 8,956 64,893     -
   Van Houte Hans Chief Financial Officer   •       –      –    2025-04-30 4 S $11.50 $28,041 D/D (2,438) 39,922     -
   Van Houte Hans Chief Financial Officer   •       –      –    2025-04-30 4 OE $0.00 $0 D/D 8,636 42,360     -
   Ring Christine Chief Legal Officer   •       –      –    2025-04-30 4 S $11.50 $33,286 D/D (2,894) 37,318     -
   Ring Christine Chief Legal Officer   •       –      –    2025-04-30 4 OE $0.00 $0 D/D 7,674 40,212     -
   Van Houte Hans Chief Financial Officer   •       –      –    2025-03-03 4 AS $14.40 $84,388 D/D (5,825) 33,724     -
  251 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 1 of 11
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2025 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us